I8132
scyllo-Inositol
≥98%, Myo-inositol isomer
Synonym(s):
1,3,5/2,4,6-Hexahydroxycyclohexane, DTLET
Sign In to View Organizational & Contract Pricing.
Select a Size
About This Item
Empirical Formula (Hill Notation):
C6H12O6
CAS Number:
Molecular Weight:
180.16
UNSPSC Code:
12352207
PubChem Substance ID:
NACRES:
NA.77
MDL number:
Product Name
scyllo-Inositol, ≥98%
SMILES string
O[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)[C@H]1O
InChI key
CDAISMWEOUEBRE-CDRYSYESSA-N
InChI
1S/C6H12O6/c7-1-2(8)4(10)6(12)5(11)3(1)9/h1-12H/t1-,2-,3+,4+,5-,6-
assay
≥98%
Quality Level
Related Categories
Other Notes
Naturally occurring isomer of myo-inositol.
Storage Class
11 - Combustible Solids
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Gloves, type N95 (US)
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Christophe Michon et al.
Communications biology, 3(1), 93-93 (2020-03-04)
A rare stereoisomer of inositol, scyllo-inositol, is a therapeutic agent that has shown potential efficacy in preventing Alzheimer's disease. Mycobacterium tuberculosis ino1 encoding myo-inositol-1-phosphate (MI1P) synthase (MI1PS) was introduced into Bacillus subtilis to convert glucose-6-phosphate (G6P) into MI1P. We found that
Sara Alam et al.
Current biology : CB, 33(11), 2175-2186 (2023-05-11)
Most eukaryotes respire oxygen, using it to generate biomass and energy. However, a few organisms have lost the capacity to respire. Understanding how they manage biomass and energy production may illuminate the critical points at which respiration feeds into central
Cheryl A Hawkes et al.
The European journal of neuroscience, 31(2), 203-213 (2010-01-16)
Beta-amyloid (Abeta) peptides are thought to play a major role in the pathogenesis of Alzheimer's disease. Compounds that disrupt the kinetic pathways of Abeta aggregation may be useful in elucidating the role of oligomeric, protofibrillar and fibrillar Abeta in the
S Salloway et al.
Neurology, 77(13), 1253-1262 (2011-09-16)
This randomized, double-blind, placebo-controlled, dose-ranging phase 2 study explored safety, efficacy, and biomarker effects of ELND005 (an oral amyloid anti-aggregation agent) in mild to moderate Alzheimer disease (AD). A total of 353 patients were randomized to ELND005 (250, 1,000, or
Sharmistha Sinha et al.
ACS chemical neuroscience, 3(6), 451-458 (2012-08-04)
Many compounds have been tested as inhibitors or modulators of amyloid β-protein (Aβ) assembly in hope that they would lead to effective, disease-modifying therapy for Alzheimer's disease (AD). These compounds typically were either designed to break apart β-sheets or selected
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service